ClinicalTrials.gg
RecruitingNCT04773366Updated Nov 20, 2026

A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protocol

A Phase 3 interventional study of Prednisone+Cytarabine+vincristine and Prednisone+Cytarabine+vincristine+Mercaptopurine in Langerhans Cell Histiocytosis, sponsored by Shanghai Children's Medical Center. Recruiting at 1 site in China. Open to participants aged 1 Day to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Shanghai Children's Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jul 2018, registered Feb 2021).
  • Started Jul 2018; still recruiting 8 years 4 months later.
Updated Nov 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
1 Day to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.

Planned enrollment
Largest of 17
200 · median 40
Started
2018
the only one that year
Phase 3
Only one
of the 17
Primary completion
2026-12
later than 4 of 12 live
Registered
4th of 17
by date
Lead sponsor
1 of 17
Shanghai Children's Medical Center

Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one has the largest planned enrollment, is the only one that started in 2018, is the only one in phase 3, reaches primary completion later than 4 of the 12 other live ones, and was the 4th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 1 Day to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Histiocytosis, Langerhans-Cell with a site in China, or all of them as a file.
02

Study summary

From January 2010 to December 2014, 150 children with MS-LCH were treated in our hospital following a LCH II (Arm B) based protocol. Treatment was based on a modification of the LCH-II (Arm B) based protocol. However, the continuation treatment was extended to 56 weeks and etoposide was omitted from the continuation treatment.

For the 59 patients with RO involvement (RO+) (the lungs are not considered a RO in the current study), the rapid response rate (week 6) was 61.0% and the 3-year overall survival (OS) 73.4±5.9%. Rapid responders had a better 3-year survival rate than poor responders (90.9±5.0% vs. 45.7±11.0%, P\<0.001). The 3-year OS in the current study is 10\~20% lower than the rates reported by Gadner et al. and Morimoto et al.. We have not yet adopted effective salvage therapies for RO+ patients with recurrent disease. During the time of this study, cladribine was unavailable. Second-line therapy for non-responders or patients with disease reactivation was individualized treatment based on the physician's experience. An effective salvage therapy is essential for this high-risk group.

For 91without RO involvement (RO-), 78 patients (85.7%) were rapid responders at week 6. The 3-year cumulative reactivation rate was 10.7% for RO- patients. No death occurred in this subgroup, with a 3-year OS of 100% in RO- patients. Compared to the LCH II and LCH III trials, the current study had a more intensive initial treatment regimen for RO- patients. However, the addition of etoposide to prednisone and vincristine in the initial therapy did not increase the 6-week response rate for RO- patients (85.7% in this study compared to 83% in the LCH II study and 86% in the LCH III study). Surprisingly, with a relatively intense initial treatment, a relatively low 3-year cumulative reactivation rate was observed in RO- patients in the current study. This result suggests that the initial treatment intensity and duration of continuation therapy both impact disease reactivation. The intensity of induction can affect the degree of disease resolution. Insufficient treatment intensity might lead to late relapse. Similarity to that observed has been in other childhood hematological malignancies. This finding deserves to be tested in prospective clinical trials with long-term follow-up. Cytarabine has been applied for patients with LCH but has never been evaluated in our hospital prospectively. In this study, we administer a cytarabine contained protocol to patients with multisystem involvement with or without risk organs involvement. The treatment results will be compared with our historical studies.

Read the detailed description

All patients with de novo pathological confirmed LCH enrolled in this study will be classified into 4 groups. Group 1: Multisystem patients (≥2 organs/systems) with involvement of one or more "Risk" organs" (hematopoietic system, liver or spleen);Group 2:Multisystem patients, but without involvement of "Risk" organs; Group 3: Single system, Multifocal+ Single system, unifocal and special site@ (Isolated lesion of special site)+ Single system, unifocal and CNS risk+Single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary+Single system, unifocal and other functionally critical anatomical sites; Group 4: Single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion). For patients in Group 1, a 6-week initial treatment, a 16-week consolidation continuation treatment and a 26-week maintenance continuation treatment containing cytarabine is applied. For patients in Group 2, a 6-week initial treatment containing cytarabine and a 46-week continuation treatment (without cytarabine) is applied. For patients in Group 3,a 6-week initial treatment and a 46-week continuation treatment (without cytarabine) is applied. For patients in Group 4, only local therapy followed by wait-and-see strategy is applied.

03

Conditions studied

  • Langerhans Cell Histiocytosis

Keywords

  • Langerhans cell histiocytosis
  • pediatric patients
  • cytarabine
  • treatment outcome
04

Who can participate

Ages eligible
1 Day to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age under 18 years
  2. Newly diagnosed LCH:Morphologic identification of the characteristic LCH cells, positive staining of the lesional cells with CD1α and/or Langerin
  3. No congenital immunodeficiency, infection, or prior organ transplant
  4. No previous chemotherapy/target therapy/radiation, if any applied, total prior steroids dosage \< prednisone 280 mg/m2

Exclusion criteria

Exclusion Criteria:

  • Patients have overwhelming infection, and a of \< 2 weeks
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Group 1

    Multisystem patients (≥2 organs/systems) with involvement of one or more "Risk" organs, i.e. hematopoietic system, liver or spleen. All patients in this group receive an initial therapy (Week 1\~6) followed by a consolidation continuation therapy (Week 7\~22) and maintenance continuation therapy (Week 25\~52).

    Drug: Prednisone+Cytarabine+vincristine · Drug: Prednisone+Cytarabine+vincristine+Mercaptopurine

  • Experimental
    Group 2

    Multisystem patients, but without involvement of "Risk" organs. All patients in this group receive an initial therapy (Week 1\~6) followed by continuation therapy (Week 7\~52).

    Drug: Prednisone+Cytarabine+vincristine · Drug: Prednisone+vincristine+Mercaptopurine

  • Experimental
    Group 3

    Includes patients with single system, multifocal or with single system, unifocal and special site (Isolated lesion of special site) or with single system, unifocal and CNS risk or with single system, unifocal i.e. thyroid, lung, thymus, hypothalamic-pituitary or with single system, unifocal and other functionally critical anatomical sites. All patients in this group receive an initial therapy (Week 1\~6) followed by continuation therapy (Week 7\~52).

    Drug: Prednisone+vincristine

  • Experimental
    Group 4

    Patients with single system, unifocal i.e. bone, skin or lymph node (not the draining lymph node of another LCH lesion). All patients in this group enter into observation after local therapy. Chemotherapy only apply to patients with disease reactivation during observation.

    Other: Local therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of responders after initial treatment for patients with risk organ involvement

    Rate of responders after initial treatment and consolidation continuation treatment. A good response is defined as complete resolution (no evidence of active disease) in risk organs.

    Time frame: Evaluation at week 6 or 12

  2. Reactivation rate for all patients

    Reactivation is defined as progression or relapse in any organ or system after disease complete resolution (no evidence of active disease).

    Time frame: Up to 5 years

Secondary outcomes

  1. Overall survival for patients with risk organ involvement

    Overall survival is measured using the Kaplan-Meier method. From the day of diagnosis to death for any reason or to the date of the last follow-up contact.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Simko SJ, McClain KL, Allen CE. Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone? Br J Haematol. 2015 Apr;169(2):299-301. doi: 10.1111/bjh.13208. Epub 2014 Nov 16. No abstract available. PubMed 25400231 ↗
  • Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, Broadbent V, Donadieu J, Henter JI, McCarter R, Ladisch S; Histiocyte Society. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1;111(5):2556-62. doi: 10.1182/blood-2007-08-106211. Epub 2007 Dec 18. PubMed 18089850 ↗
  • Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Potschger U, Pritchard J, Ladisch S; Histiocyte Society. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May;138(5):728-34. doi: 10.1067/mpd.2001.111331. PubMed 11343051 ↗
  • Egeler RM, de Kraker J, Voute PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol. 1993;21(4):265-70. doi: 10.1002/mpo.2950210406. PubMed 8469221 ↗
  • Weitzman S, Braier J, Donadieu J, Egeler RM, Grois N, Ladisch S, Potschger U, Webb D, Whitlock J, Arceci RJ. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009 Dec 15;53(7):1271-6. doi: 10.1002/pbc.22229. PubMed 19731321 ↗
  • Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliote A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17;126(12):1415-23. doi: 10.1182/blood-2015-03-635151. Epub 2015 Jul 20. PubMed 26194764 ↗
  • Braier J, Rosso D, Pollono D, Rey G, Lagomarsino E, Latella A, Zubizarreta P. Symptomatic bone langerhans cell histiocytosis treated at diagnosis or after reactivation with indomethacin alone. J Pediatr Hematol Oncol. 2014 Jul;36(5):e280-4. doi: 10.1097/MPH.0000000000000165001. PubMed 24977402 ↗
  • Heritier S, Jehanne M, Leverger G, Emile JF, Alvarez JC, Haroche J, Donadieu J. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncol. 2015 Sep;1(6):836-8. doi: 10.1001/jamaoncol.2015.0736. No abstract available. PubMed 26180941 ↗
  • Gao YJ, Su M, Tang JY, Pan C, Chen J. Treatment Outcome of Children With Multisystem Langerhans Cell Histiocytosis: The Experience of a Single Children's Hospital in Shanghai, China. J Pediatr Hematol Oncol. 2018 Jan;40(1):e9-e12. doi: 10.1097/MPH.0000000000001016. PubMed 29200145 ↗
  • Su M, Gao YJ, Pan C, Chen J, Tang JY. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China. Pediatr Hematol Oncol. 2018 Oct-Nov;35(7-8):385-392. doi: 10.1080/08880018.2018.1545814. Epub 2019 Jan 29. PubMed 30693828 ↗
  • Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013 Jun 20;121(25):5006-14. doi: 10.1182/blood-2012-09-455774. Epub 2013 Apr 15. PubMed 23589673 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2018 (actual). Primary completion is estimated for Dec 2026, 101 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Jun 2023 → Dec 2026 and completion Jun 2026 → Dec 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Feb 26, 2021
StartActual
Jul 1, 2018
Primary completionEst.
Dec 31, 2026was Jun 2023
CompletionEst.
Dec 30, 2031was Jun 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2023→Dec 31, 2026
Nov 20, 2026
Study completion
Jun 30, 2026→Dec 30, 2031
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Primary completion Jun 30, 2023→Dec 31, 2026
    Study completion Jun 30, 2026→Dec 30, 2031
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04773366
Lead sponsor
Shanghai Children's Medical Center
Responsible party
Sponsor
First posted
Feb 26, 2021
Start date
Jul 1, 2018
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 30, 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Meng Su, MD
Contact
sumeng@scmc.com.cn
0086-18817821853
Ya-Li Han, MD
Contact
hanyali@scmc.com.cn
0086-21-38626288
Yi-Jin Gao, MD
principal investigator · Shanghai Children's Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisone · Cytarabine · Vincristine · Mercaptopurine

Start the discussion